Roth Capital initiated coverage on vTv Therapeutics with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for VTVT
Across the 4 sessions after earlier VTVT headlines, the stock closed higher 4 times and lower 0 times, with a median move of 5.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VTVT | SPY |
|---|---|---|---|
| Jan 5, 2026 | TD Cowen initiated coverage on vTv Therapeutics with a new price target | +7.0% | +0.7% |
| Dec 19, 2025 | vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | +3.7% | +0.6% |
| Nov 19, 2025 | BTIG Research initiated coverage on vTv Therapeutics with a new price target | +7.1% | +0.4% |
| Nov 7, 2025 | vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | +2.2% | +0.1% |
Quantisnow market dataNASDAQ
VTVT
vTv Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for VTVT
Full VTVT profile on Quantisnow Follow VTVT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time